21MB086N Prediction: Radiomics-Based Prediction of Severe Immune-Related Adverse Events in Patients with Lung Cancer
FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE
The Innovation Office
InnovationMarketing@Moffitt.org
(813) 745-6828